To the best of our knowledge, this is the first meta-analysis to evaluate the efficacy of the platelet P2Y12 inhibitor in the treatment of migraine, which correlates closely with clinical practice and helps at least specific subsets of migraineurs benefiting from this medication. The gene discussed is P2RY12; the disease is migraine disorder.